10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||||||||||||
| |||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
REGENERON PHARMACEUTICALS, INC. | |||
Ticker: REGN Fiscal Year: 2021 | |||
CONSOLIDATED STATEMENTS OF CASH FLOWS | |||
Period Ending Dec 31, 2021 10-K (Filed: Feb 7, 2022) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
| Cash flows from operating activities: | |||
| Net income | $ 8,075,300 | 3,513,200 | 2,115,800 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation and amortization | 286,200 | 235,900 | 210,300 |
| Non-cash compensation expense | 601,700 | 432,000 | 464,300 |
| Gains on marketable and other securities, net | (387,000) | (221,800) | (131,500) |
| Other non-cash items, net | 568,700 | 86,800 | 102,200 |
| Deferred taxes | (147,100) | 75,600 | (130,600) |
| Changes in assets and liabilities: | |||
| Increase in accounts receivable | (1,927,400) | (1,356,100) | (523,700) |
| Increase in inventories | (494,300) | (529,400) | (335,500) |
| (Increase) decrease in prepaid expenses and other assets | (240,700) | 114,900 | (79,800) |
| (Decrease) increase in deferred revenue | (120,200) | 148,100 | 139,500 |
| Increase in accounts payable, accrued expenses, and other liabilities | 866,100 | 118,900 | 599,000 |
| Total adjustments | (994,000) | (895,100) | 314,200 |
| Net cash provided by operating activities | 7,081,300 | 2,618,100 | 2,430,000 |
| Cash flows from investing activities: | |||
| Purchases of marketable and other securities | (7,048,100) | (3,241,000) | (3,202,400) |
| Sales or maturities of marketable and other securities | 2,215,300 | 3,785,000 | 1,604,200 |
| Capital expenditures | (551,900) | (614,600) | (429,600) |
| Net cash used in investing activities | (5,384,700) | (70,600) | (2,027,800) |
| Cash flows from financing activities: | |||
| Proceeds from issuance of Common Stock | 1,672,300 | 2,575,200 | 211,800 |
| Payments in connection with Common Stock tendered for employee tax obligations | (1,032,700) | (680,800) | (188,000) |
| Repurchases of Common Stock | (1,645,400) | (5,846,800) | (275,900) |
| Proceeds from issuance of long-term debt | 0 | 1,981,900 | 0 |
| Proceeds from bridge loan facility | 0 | 1,500,000 | 0 |
| Repayment of bridge loan facility | 0 | (1,500,000) | 0 |
| Net cash used in financing activities | (1,005,800) | (1,970,500) | (252,100) |
| Net increase in cash, cash equivalents, and restricted cash | 690,800 | 577,000 | 150,100 |
| Cash, cash equivalents, and restricted cash at beginning of period | 2,207,300 | 1,630,300 | |
| Cash, cash equivalents, and restricted cash at end of period | 2,898,100 | 2,207,300 | 1,630,300 |
| Supplemental disclosure of cash flow information | |||
| Cash paid for interest (net of amounts capitalized) | 55,800 | 23,200 | 25,000 |
| Cash paid for income taxes | 1,218,400 | 188,100 | 342,300 |
| External Links | |
| REGENERON PHARMACEUTICALS, INC. (REGN) Fiscal Year 2021 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |